SCHEMBL3088948

SCHEMBL3088948

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccc(Cl)c(Cl)c2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.47
BCL2L1 Q07817 1/20 0.47
MCL1 Q07820 1/20 0.47
BCL2 P10415 1/20 0.44
GPR27 Q9NS67 1/20 0.43
PIK3CD O00329 1/20 0.42
PIK3C2B O00750 1/20 0.42
AURKA O14965 1/20 0.42
PIK3C2G O75747 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
CDK2 P24941 1/20 0.42
MAPK3 P27361 1/20 0.42
MAPK1 P28482 1/20 0.42
CCND3 P30281 1/20 0.42
MAPK4 P31152 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090974 0.92 MEN1 (0.50) PRMT1GPR27GAAMEN1KMT2A
SCHEMBL3097645 0.90 KAT6A (0.49) BCL2L1MCL1GPR27GAAMEN1
SCHEMBL3093901 0.90 MMP9 (0.46) PRMT1GPR27MEN1KMT2ALMNA
SCHEMBL3102970 0.90 MMP9 (0.46) PRMT1GPR27MEN1KMT2ALMNA
SCHEMBL3090792 0.89 NPC1 (0.51) GPR27GAAMEN1KMT2ALMNA
SCHEMBL3092998 0.89 NPC1 (0.51) GPR27GAAMEN1KMT2ALMNA
SCHEMBL3086202 0.89 SMO (0.46) GPR27GAAMEN1KMT2ALMNA
SCHEMBL3093732 0.88 LARS1 (0.44) PRMT1GPR27GAAMEN1KMT2A
SCHEMBL3090637 0.88 RAB9A (0.48) GPR27MEN1KMT2ALMNAKDM4E
SCHEMBL3100199 0.88 NPC1 (0.53) GAAMEN1KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 PRMT1 3807/4885BCL2L1 3351/4885MCL1 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.